Strontium-89 treatment for prostate cancer bone metastases: Does a prostate-specific antigen response predict for improved survival?

Australasian Radiology

Volumn 45, Issue 1, 2001, Pages 39-42

  Zyskowski, Adam ^a   Lamb, David ^a   Morum, Pauline ^a   Hamilton, David ^a   Johnson, Carol ^a  

^a WELLINGTON HOSPITAL   (New Zealand)

Author keywords

Prostate cancer; Prostate specific antigen; Strontium 89; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STRONTIUM 89;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIOISOTOPE THERAPY; TREATMENT OUTCOME;

AGED; BONE NEOPLASMS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; STRONTIUM RADIOISOTOPES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035083529     PISSN: 00048461     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1673.2001.00871.x     Document Type: Article

References (11)

1. Prostate specific antigen after external beam radiotherapy for prostate cancer: Followup
2. Prostate-specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?
3. Results of a randomised phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
4. Strontium-89 chloride for the palliation in prostatic skeletal malignancy
5. Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate
6. Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease
7. Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
8. Clinical experience with strontium-89 in prostatic and breast cancer
9. A prospective, randomised double-blind crossover study to examine the efficacy in pain palliation in patients with advanced prostate cancer metastatic to bone
10. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer
11. Strontium-89 for symptomatic metastatic prostate cancer to bone: Recommendations for hospice patients